CCS
BIIB icon

Crosspoint Capital Strategies’s Biogen BIIB Stock Holding History

Crosspoint Capital Strategies’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		$1.21M Buy
+4,384
New +$1.24M 2.41% 27
2016
Q1 		– Sell
-12
Closed -$4K – 183
2015
Q4 		$4K Sell
12
-9
-43% -$2.59K ﹤0.01% 829
2015
Q3 		$6K Buy
+21
New +$6.93K 0.01% 477

Other funds holding BIIB

Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Crosspoint Capital Strategies's BIIB Position: Q4 2022 in Review

Crosspoint Capital Strategies opened a new position in Biogen (BIIB) in Q4 2022: 4,384 shares worth $1.21M. The stake represents 2.41% of the portfolio and ranks #27 among its holdings. This is a return to the name: Crosspoint Capital Strategies previously reported a position in BIIB as recently as Q4 2015.

Crosspoint Capital Strategies first reported a position in BIIB in Q3 2015 and has held it in 3 quarters since. 1,031 funds tracked by Wall St. Rank hold BIIB as of Q4 2022.

  • Crosspoint Capital Strategies held 4,384 shares of Biogen worth $1.21M as of Q4 2022.
  • Biogen was a new Crosspoint Capital Strategies position in Q4 2022.
  • Biogen made up 2.41% of Crosspoint Capital Strategies's portfolio in Q4 2022, its #27 holding.
  • Crosspoint Capital Strategies first reported a position in Biogen in Q3 2015 and has held it in 3 quarters since.
  • 1,031 funds tracked by Wall St. Rank held Biogen as of Q4 2022.

Based on Crosspoint Capital Strategies's 13F filing for Q4 2022, filed 13 Feb 2023.